세계의 환각제 API 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for psychedelic APIs. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global psychedelic API market from 2025 to 2032.

Key Insights:

• Psychedelic API Market Size (2025E): US$ 2.4 Bn
• Projected Market Value (2032F): US$ 5.6 Bn
• Global Market Growth Rate (CAGR 2025 to 2032):13.2%

Psychedelic API Market - Report Scope:

Psychedelic APIs are key components in the development of psychedelic-based therapeutics, which are gaining traction for the treatment of mental health disorders, including depression, PTSD, anxiety, and substance use disorders. These APIs, including psilocybin, LSD, DMT, MDMA, and ketamine, are being extensively studied for their potential to revolutionize psychiatric care. The psychedelic API market caters to pharmaceutical companies, research institutions, and compounding pharmacies, offering high-purity active ingredients for clinical trials and therapeutic applications. Market growth is driven by increasing investment in psychedelic drug research, regulatory shifts supporting medical use, and rising demand for novel mental health treatments.

Market Growth Drivers:

The global psychedelic API market is propelled by several key factors, including growing awareness of psychedelic-assisted therapy as a breakthrough treatment for mental health disorders. The rising prevalence of depression, anxiety, and PTSD has intensified the demand for alternative treatments, prompting pharmaceutical companies and biotech firms to invest heavily in psychedelic drug development. Regulatory advancements, such as the FDA's designation of psilocybin and MDMA as breakthrough therapies, further accelerate market expansion. Additionally, the increasing number of clinical trials and research collaborations focused on understanding the therapeutic potential of psychedelic compounds fosters innovation and market growth.

Market Restraints:

Despite promising growth prospects, the psychedelic API market faces challenges related to regulatory restrictions, ethical concerns, and limited manufacturing capabilities. The classification of many psychedelic substances as Schedule I drugs under global drug control treaties poses significant hurdles for research and commercialization. Additionally, the stigma associated with psychedelics, coupled with varying regulations across different countries, complicates market penetration. High production costs and stringent quality control requirements further limit the availability of pharmaceutical-grade psychedelic APIs, impacting scalability and accessibility.

Market Opportunities:

The psychedelic API market presents significant growth opportunities driven by advancements in drug formulation, the expansion of mental health awareness initiatives, and increasing private and public sector investments. The integration of digital health platforms and AI-driven drug discovery techniques enhances research capabilities and facilitates the development of next-generation psychedelic therapeutics. Moreover, the potential applications of psychedelics beyond mental health, such as in neurodegenerative diseases, chronic pain management, and end-of-life care, expand the market scope. Strategic partnerships between biotech firms, academic institutions, and government bodies will be crucial in navigating regulatory landscapes and accelerating the commercialization of psychedelic-based therapies.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the psychedelic API market globally?
• Which psychedelic compounds and applications are leading the adoption of psychedelic therapeutics?
• How are regulatory advancements shaping the competitive landscape of the psychedelic API market?
• Who are the key players contributing to the psychedelic API market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global psychedelic API market?

Competitive Intelligence and Business Strategy:

Leading players in the global psychedelic API market, including Compass Pathways, MindMed, ATAI Life Sciences, Cybin Inc., and Usona Institute, focus on research innovation, regulatory approvals, and strategic partnerships to gain a competitive edge. These companies are investing in clinical trials, novel drug formulations, and scalable production methods to support the commercialization of psychedelic-based medicines. Collaborations with mental health organizations, research institutions, and policymakers facilitate market entry and accelerate drug development timelines. Additionally, the emphasis on patient advocacy, public education, and regulatory engagement fosters market acceptance and long-term growth in the evolving psychedelic API landscape.

Key Companies Profiled:

• Compass Pathways
• MindMed
• ATAI Life Sciences
• Cybin Inc.
• Usona Institute
• GH Research
• Beckley Psytech
• Seelos Therapeutics
• Small Pharma
• Tryp Therapeutics

Psychedelic API Market Segmentation

By Product Type

• API-Grade Psilocybin
• API-Grade DMT
• LSD API
• MDMA API
• Ketamine API

By API Compound

• Active Plant Components
• Novel Synthetic Compounds
• Metabolites
• Isotopically Labelled Standards

By Source

• Natural
• Synthetic
• Bio-Synthetic

By Grade

• GMP
• Non-GMP

By Application

• Clinical
• Research

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Psychedelic API Market Snapshot, 2025 and 2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overviews

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Drug Adoption Analysis
• 3.2. Value Chain Analysis
  • 3.2.1. List of Sourcer/Marketplaces
    • 3.2.1.1. Retail
    • 3.2.1.2. E-Commerce
  • 3.2.2. List of Indication (Industry)
• 3.3. Key Deals and Mergers
• 3.4. PESTLE Analysis
• 3.5. Porter's Five Force Analysis

4. Global Psychedelic API Market Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn ) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn ) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn ) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Bn ) Analysis and Forecast, 2025-2032
• 4.3. Global Psychedelic API Market Outlook: Product Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn ) Analysis, By Product Type, 2019-2024
  • 4.3.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
    • 4.3.3.1. API-Grade Psilocybin
    • 4.3.3.2. API-Grade DMT
    • 4.3.3.3. LSD API
    • 4.3.3.4. MDMA API
    • 4.3.3.5. Ketamine API
    • 4.3.3.6. Others
  • 4.3.4. Market Attractiveness Analysis: Product Type
• 4.4. Global Psychedelic API Market Outlook: API Compound
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Bn ) Analysis, By API Compound, 2019-2024
  • 4.4.3. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
    • 4.4.3.1. Active Plant Components
    • 4.4.3.2. Novel Synthetic Compounds
    • 4.4.3.3. Metabolites
    • 4.4.3.4. Isotopically Labelled Standards
  • 4.4.4. Market Attractiveness Analysis: API Compound
• 4.5. Global Psychedelic API Market Outlook: Source
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn ) Analysis, By Source, 2019-2024
  • 4.5.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
    • 4.5.3.1. Natural
    • 4.5.3.2. Synthetic
    • 4.5.3.3. Bio-Synthetic
  • 4.5.4. Market Attractiveness Analysis: Source
• 4.6. Global Psychedelic API Market Outlook: Grade
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Bn ) Analysis, By Grade, 2019-2024
  • 4.6.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
    • 4.6.3.1. GMP
    • 4.6.3.2. Non-GMP
  • 4.6.4. Market Attractiveness Analysis: Grade
• 4.7. Global Psychedelic API Market Outlook: Application
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn ) Analysis, By Application, 2019-2024
  • 4.7.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
    • 4.7.3.1. Clinical
    • 4.7.3.2. Research
  • 4.7.4. Market Attractiveness Analysis: Application

5. Global Psychedelic API Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn ) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Psychedelic API Market Outlook

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Product Type
  • 6.2.3. By API Compound
  • 6.2.4. By Source
  • 6.2.5. By Grade
  • 6.2.6. By Application
• 6.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
  • 6.4.1. API-Grade Psilocybin
  • 6.4.2. API-Grade DMT
  • 6.4.3. LSD API
  • 6.4.4. MDMA API
  • 6.4.5. Ketamine API
  • 6.4.6. Others
• 6.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
  • 6.5.1. Active Plant Components
  • 6.5.2. Novel Synthetic Compounds
  • 6.5.3. Metabolites
  • 6.5.4. Isotopically Labelled Standards
• 6.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
  • 6.6.1. Natural
  • 6.6.2. Synthetic
  • 6.6.3. Bio-Synthetic
• 6.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
  • 6.7.1. GMP
  • 6.7.2. Non-GMP
• 6.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
  • 6.8.1. Clinical
  • 6.8.2. Research
• 6.9. Market Attractiveness Analysis

7. Europe Psychedelic API Market Outlook

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Product Type
  • 7.2.3. By API Compound
  • 7.2.4. By Source
  • 7.2.5. By Grade
  • 7.2.6. By Application
• 7.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
  • 7.4.1. API-Grade Psilocybin
  • 7.4.2. API-Grade DMT
  • 7.4.3. LSD API
  • 7.4.4. MDMA API
  • 7.4.5. Ketamine API
  • 7.4.6. Others
• 7.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
  • 7.5.1. Active Plant Components
  • 7.5.2. Novel Synthetic Compounds
  • 7.5.3. Metabolites
  • 7.5.4. Isotopically Labelled Standards
• 7.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
  • 7.6.1. Natural
  • 7.6.2. Synthetic
  • 7.6.3. Bio-Synthetic
• 7.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
  • 7.7.1. GMP
  • 7.7.2. Non-GMP
• 7.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
  • 7.8.1. Clinical
  • 7.8.2. Research
• 7.9. Market Attractiveness Analysis

8. East Asia Psychedelic API Market Outlook

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Product Type
  • 8.2.3. By API Compound
  • 8.2.4. By Source
  • 8.2.5. By Grade
  • 8.2.6. By Application
• 8.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
  • 8.4.1. API-Grade Psilocybin
  • 8.4.2. API-Grade DMT
  • 8.4.3. LSD API
  • 8.4.4. MDMA API
  • 8.4.5. Ketamine API
  • 8.4.6. Others
• 8.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
  • 8.5.1. Active Plant Components
  • 8.5.2. Novel Synthetic Compounds
  • 8.5.3. Metabolites
  • 8.5.4. Isotopically Labelled Standards
• 8.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
  • 8.6.1. Natural
  • 8.6.2. Synthetic
  • 8.6.3. Bio-Synthetic
• 8.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
  • 8.7.1. GMP
  • 8.7.2. Non-GMP
• 8.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
  • 8.8.1. Clinical
  • 8.8.2. Research
• 8.9. Market Attractiveness Analysis

9. South Asia and Oceania Psychedelic API Market Outlook

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Product Type
  • 9.2.3. By API Compound
  • 9.2.4. By Source
  • 9.2.5. By Grade
  • 9.2.6. By Application
• 9.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
  • 9.4.1. API-Grade Psilocybin
  • 9.4.2. API-Grade DMT
  • 9.4.3. LSD API
  • 9.4.4. MDMA API
  • 9.4.5. Ketamine API
  • 9.4.6. Others
• 9.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
  • 9.5.1. Active Plant Components
  • 9.5.2. Novel Synthetic Compounds
  • 9.5.3. Metabolites
  • 9.5.4. Isotopically Labelled Standards
• 9.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
  • 9.6.1. Natural
  • 9.6.2. Synthetic
  • 9.6.3. Bio-Synthetic
• 9.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
  • 9.7.1. GMP
  • 9.7.2. Non-GMP
• 9.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
  • 9.8.1. Clinical
  • 9.8.2. Research
• 9.9. Market Attractiveness Analysis

10. Latin America Psychedelic API Market Outlook

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Product Type
  • 10.2.3. By API Compound
  • 10.2.4. By Source
  • 10.2.5. By Grade
  • 10.2.6. By Application
• 10.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
  • 10.4.1. API-Grade Psilocybin
  • 10.4.2. API-Grade DMT
  • 10.4.3. LSD API
  • 10.4.4. MDMA API
  • 10.4.5. Ketamine API
  • 10.4.6. Others
• 10.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
  • 10.5.1. Active Plant Components
  • 10.5.2. Novel Synthetic Compounds
  • 10.5.3. Metabolites
  • 10.5.4. Isotopically Labelled Standards
• 10.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
  • 10.6.1. Natural
  • 10.6.2. Synthetic
  • 10.6.3. Bio-Synthetic
• 10.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
  • 10.7.1. GMP
  • 10.7.2. Non-GMP
• 10.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
  • 10.8.1. Clinical
  • 10.8.2. Research
• 10.9. Market Attractiveness Analysis

11. Middle East & Africa Psychedelic API Market Outlook

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Product Type
  • 11.2.3. By API Compound
  • 11.2.4. By Source
  • 11.2.5. By Grade
  • 11.2.6. By Application
• 11.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product Type, 2025-2032
  • 11.4.1. API-Grade Psilocybin
  • 11.4.2. API-Grade DMT
  • 11.4.3. LSD API
  • 11.4.4. MDMA API
  • 11.4.5. Ketamine API
  • 11.4.6. Others
• 11.5. Current Market Size (US$ Bn ) Analysis and Forecast, By API Compound, 2025-2032
  • 11.5.1. Active Plant Components
  • 11.5.2. Novel Synthetic Compounds
  • 11.5.3. Metabolites
  • 11.5.4. Isotopically Labelled Standards
• 11.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Source, 2025-2032
  • 11.6.1. Natural
  • 11.6.2. Synthetic
  • 11.6.3. Bio-Synthetic
• 11.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Grade, 2025-2032
  • 11.7.1. GMP
  • 11.7.2. Non-GMP
• 11.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Application, 2025-2032
  • 11.8.1. Clinical
  • 11.8.2. Research
• 11.9. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Core One Labs Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Cayman Chemical Company (Matreya)
  • 12.3.3. COMPASS Pathways plc
  • 12.3.4. Beckley Psytech
  • 12.3.5. Atai Life Sciences
  • 12.3.6. Tryp Therapeutics
  • 12.3.7. Filament Health
  • 12.3.8. Ceruvia Lifesciences, LLC
  • 12.3.9. BetterLife Pharma
  • 12.3.10. Psygen Pharmaceutical
  • 12.3.11. Mindset Pharma

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations